These findings indicate that although metabolic and cardiovascular comorbidities may modulate PDPN levels indirectly, PDPN elevation in OC is predominantly driven by tumor-related inflammatory and oncogenic mechanisms, supporting the robustness of PDPN as a diagnostic biomarker independent of common comorbidities. Here, PDPN is linked to neoplasm.